Silk Road Medical downgraded to Hold from Buy at Lake Street

Lake Street analyst Frank Takkinen downgraded Silk Road Medical (SILK) to Hold from Buy with a price target of $27.50, down from $28, after the company agreed to be acquired by Boston Scientific (BSX) for $27.50 in cash per share. If an additional buyer were to come over the top, the firm thinks likely bidders could include Johnson & Johnson (JNJ) or Abbott (ABT), but Lake Street expects the deal to “close as is,” the analyst tells investors.